Search

Displaying results 4591 - 4600 of 10000 in total
  1. Drug

    Caldaret

    go.drugbank.com/drugs/DB06231
    Investigational

  2. Drug

    Limaprost

    go.drugbank.com/drugs/DB09211
    Investigational

    Ono and DSP also discontinued the development of limaprost alfadex for the additional indication of cervical spondylosis in 2008 due to the failure to demonstrate the anticipated efficacy in a Phase II … It also improves poor blood flow in the nerve tissue in cervical spondylosis and normalizes nerve function.

  3. Drug

    DDP-225

    go.drugbank.com/drugs/DB05642
    Investigational

    DDP225 is both a noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist. … The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases.

  4. Drug

    Relacatib

    go.drugbank.com/drugs/DB06367
    Investigational

  5. Drug

    LX6171

    go.drugbank.com/drugs/DB05180
    Investigational

    LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia

  6. Drug

    Oblimersen

    go.drugbank.com/drugs/DB13811
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    1,10-Phenanthroline

    go.drugbank.com/drugs/DB02365
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  9. Drug

    NRP409

    go.drugbank.com/drugs/DB05235
    Experimental

    NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.

  10. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid … [F3910] eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to diseased cells enabling the cells to carry out dsRNA production internally thereby invoking